GIST tumors linked to NF1 mutations, genetic testing needed

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A specific region of the small bowel, called the duodenal-jejunal flexure, shows a high frequency of gastrointestinal stromal tumors with mutations of the NF1 gene, according to researchers at UC San Diego Moores Cancer Center, Memorial Sloan Kettering Cancer Center and Fox Chase Cancer Center. The small bowel, where approximately 30 percent of all GISTs occur, is divided into three anatomically, histologically and functionally distinct segments: the duodenum, jejunum and ileum. Most small bowel GISTs are associated with KIT mutations. However, a subset of GISTs have mutations in other genes, such as NF1.“Where the duodenum transitions into the jejunum, we are finding an over-representation of NF1-mutated GIST,” said Jason Sicklick, a surgical oncologist at Moores Cancer Center.NF1 can be mutated both somatically (within tumor DNA) or in the germline (part of the hereditary condition called Neurofibromatosis type I). Patients with NF-1 are 34 times more likely to develop GIST than unaffected individuals.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL). 
Over the past three decades, cancer genetics has transformed precision oncology. Germline testing has advanced from single-gene Sanger sequencing to parallel sequencing of hundreds of genes, while tumor (somatic) testing has expanded with the rise of targeted therapies based on point mutations, copy number changes and other alterations. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login